Fei Yang
- Cancer Research top 1%
- Breast Cancer Treatment Studies 9
- Cancer Genomics and Diagnostics 8
- Cancer-related molecular mechanisms research 6
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 10
- HER2/EGFR in Cancer Research 7
- Molecular Biology top 2%
- Immunology and Allergy top 5%
- Cell Biology top 5%
- melanin and skin pigmentation 9
-
- Mast cells and histamine 8
- Immunotherapy and Immune Responses 5
- Co-authors
- Anieta M. SieuwertsMieke TimmermansMaxime P. LookJack X. YuDmitri TalantovJohn A. FoekensMarion E. Meijer‐van GelderJan G.M. Klijn
- Journals
- Cancer Research (5 papers)Journal of Clinical Oncology (5 papers)Frontiers in Oncology (4 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Fei Yang
100 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 141
- Cancer Research 1.6k
- Oncology 1.5k
- Molecular Biology 3.0k
- Immunology and Allergy 106
- Cell Biology 275
Countries citing papers authored by Fei Yang
This map shows the geographic impact of Fei Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Yang more than expected).
Fields of papers citing papers by Fei Yang
This network shows the impact of papers produced by Fei Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Yang. The network helps show where Fei Yang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fei Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 12 | |
| 6 | 2023 | 17 | |
| 7 | 2022 | 6 | |
| 8 | CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemiabreakdown → | 2022 | 109 |
| 9 | 2022 | 8 | |
| 10 | 2022 | 5 | |
| 11 | 2022 | 25 | |
| 12 | 2022 | 10 | |
| 13 | 2021 | 8 | |
| 14 | 2021 | 1 | |
| 15 | 2021 | 17 | |
| 16 | 2019 | 56 | |
| 17 | 2018 | 2 | |
| 18 | Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. | 2014 | 17 |
| 19 | 2014 | 1 | |
| 20 | 2011 | 51 |
About Fei Yang
Fei Yang is a scholar working on Cancer Research, Oncology, Immunology and Allergy, Immunology and Dermatology, having authored 108 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), Breast Cancer Treatment Studies (9 papers), melanin and skin pigmentation (9 papers), Cancer Genomics and Diagnostics (8 papers), Mast cells and histamine (8 papers), HER2/EGFR in Cancer Research (7 papers), Cancer-related molecular mechanisms research (6 papers) and Immunotherapy and Immune Responses (5 papers). The work is most often cited by research in Cancer Research (1.6k citations), Oncology (1.5k citations), Molecular Biology (3.0k citations), Immunology and Allergy (106 citations) and Cell Biology (275 citations). Fei Yang has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Anieta M. Sieuwerts, Mieke Timmermans, Maxime P. Look, Jack X. Yu, Dmitri Talantov, John A. Foekens, Marion E. Meijer‐van Gelder, Jan G.M. Klijn, Yi Zhang and David Atkins. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Frontiers in Oncology, npj Breast Cancer and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.